ID   ACOX1_HUMAN             Reviewed;         660 AA.
AC   Q15067; A8K6X8; A8KAA0; B4DK61; F5GYQ8; Q12863; Q15068; Q15101; Q16131;
AC   Q7Z3W5; Q9UD31;
DT   01-NOV-1997, integrated into UniProtKB/Swiss-Prot.
DT   20-FEB-2007, sequence version 3.
DT   07-APR-2021, entry version 207.
DE   RecName: Full=Peroxisomal acyl-coenzyme A oxidase 1 {ECO:0000303|PubMed:8117268};
DE            Short=AOX {ECO:0000303|PubMed:8117268};
DE            EC=1.3.3.6 {ECO:0000269|PubMed:17603022};
DE   AltName: Full=Palmitoyl-CoA oxidase {ECO:0000303|PubMed:14702039};
DE   AltName: Full=Straight-chain acyl-CoA oxidase {ECO:0000303|PubMed:15060085};
DE            Short=SCOX {ECO:0000303|PubMed:15060085};
DE   Contains:
DE     RecName: Full=Peroxisomal acyl-CoA oxidase 1, A chain {ECO:0000250|UniProtKB:P07872};
DE   Contains:
DE     RecName: Full=Peroxisomal acyl-CoA oxidase 1, B chain {ECO:0000250|UniProtKB:P07872};
DE   Contains:
DE     RecName: Full=Peroxisomal acyl-CoA oxidase 1, C chain {ECO:0000250|UniProtKB:P07872};
GN   Name=ACOX1 {ECO:0000312|HGNC:HGNC:119}; Synonyms=ACOX;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] (ISOFORMS 1 AND 2).
RX   PubMed=8159712; DOI=10.1073/pnas.91.8.3107;
RA   Varanasi U., Chu R., Chu S., Espinosa R., Lebeau M.M., Reddy J.K.;
RT   "Isolation of the human peroxisomal acyl-CoA oxidase gene: organization,
RT   promoter analysis, and chromosomal localization.";
RL   Proc. Natl. Acad. Sci. U.S.A. 91:3107-3111(1994).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RC   TISSUE=Liver;
RX   PubMed=7876265; DOI=10.1074/jbc.270.9.4908;
RA   Chu R., Varanasi U., Chu S., Lin Y., Usuda N., Rao M.S., Reddy J.K.;
RT   "Overexpression and characterization of the human peroxisomal acyl-CoA
RT   oxidase in insect cells.";
RL   J. Biol. Chem. 270:4908-4915(1995).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 2), VARIANT MET-312, AND INVOLVEMENT IN
RP   PSEUDO-NALD.
RC   TISSUE=Liver;
RX   PubMed=8040306; DOI=10.1172/jci117365;
RA   Fourner B., Saudubray J.-M., Benichou B., Lyonnet S., Munnich A.,
RA   Clevers H., Poll-The B.T.;
RT   "Large deletion of the peroxisomal acyl-CoA oxidase gene in pseudoneonatal
RT   adrenoleukodystrophy.";
RL   J. Clin. Invest. 94:526-531(1994).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), AND VARIANT MET-312.
RC   TISSUE=Liver;
RX   PubMed=8117268; DOI=10.1006/bbrc.1994.1158;
RA   Aoyama T., Tsushima K., Souri M., Kamijo T., Suzuki Y., Shimozawa N.,
RA   Orii T., Hashimoto T.;
RT   "Molecular cloning and functional expression of a human peroxisomal acyl-
RT   coenzyme A oxidase.";
RL   Biochem. Biophys. Res. Commun. 198:1113-1118(1994).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1; 2 AND 3), AND VARIANT
RP   MET-312.
RC   TISSUE=Placenta, Thalamus, and Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANT MET-312.
RC   TISSUE=Retina;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H., Heubner D.,
RA   Hoerlein A., Michel G., Wedler H., Koehrer K., Ottenwaelder B., Poustka A.,
RA   Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16625196; DOI=10.1038/nature04689;
RA   Zody M.C., Garber M., Adams D.J., Sharpe T., Harrow J., Lupski J.R.,
RA   Nicholson C., Searle S.M., Wilming L., Young S.K., Abouelleil A.,
RA   Allen N.R., Bi W., Bloom T., Borowsky M.L., Bugalter B.E., Butler J.,
RA   Chang J.L., Chen C.-K., Cook A., Corum B., Cuomo C.A., de Jong P.J.,
RA   DeCaprio D., Dewar K., FitzGerald M., Gilbert J., Gibson R., Gnerre S.,
RA   Goldstein S., Grafham D.V., Grocock R., Hafez N., Hagopian D.S., Hart E.,
RA   Norman C.H., Humphray S., Jaffe D.B., Jones M., Kamal M., Khodiyar V.K.,
RA   LaButti K., Laird G., Lehoczky J., Liu X., Lokyitsang T., Loveland J.,
RA   Lui A., Macdonald P., Major J.E., Matthews L., Mauceli E., McCarroll S.A.,
RA   Mihalev A.H., Mudge J., Nguyen C., Nicol R., O'Leary S.B., Osoegawa K.,
RA   Schwartz D.C., Shaw-Smith C., Stankiewicz P., Steward C., Swarbreck D.,
RA   Venkataraman V., Whittaker C.A., Yang X., Zimmer A.R., Bradley A.,
RA   Hubbard T., Birren B.W., Rogers J., Lander E.S., Nusbaum C.;
RT   "DNA sequence of human chromosome 17 and analysis of rearrangement in the
RT   human lineage.";
RL   Nature 440:1045-1049(2006).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2), AND VARIANTS ILE-153
RP   AND MET-312.
RC   TISSUE=Colon, and Eye;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   FUNCTION.
RX   PubMed=15060085; DOI=10.1194/jlr.m300512-jlr200;
RA   Ferdinandusse S., Denis S., Van Roermund C.W., Wanders R.J., Dacremont G.;
RT   "Identification of the peroxisomal beta-oxidation enzymes involved in the
RT   degradation of long-chain dicarboxylic acids.";
RL   J. Lipid Res. 45:1104-1111(2004).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=17081983; DOI=10.1016/j.cell.2006.09.026;
RA   Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P., Mann M.;
RT   "Global, in vivo, and site-specific phosphorylation dynamics in signaling
RT   networks.";
RL   Cell 127:635-648(2006).
RN   [12]
RP   FUNCTION, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, TISSUE SPECIFICITY, AND
RP   CATALYTIC ACTIVITY.
RX   PubMed=17603022; DOI=10.1016/j.bbrc.2007.06.059;
RA   Oaxaca-Castillo D., Andreoletti P., Vluggens A., Yu S., van Veldhoven P.P.,
RA   Reddy J.K., Cherkaoui-Malki M.;
RT   "Biochemical characterization of two functional human liver acyl-CoA
RT   oxidase isoforms 1a and 1b encoded by a single gene.";
RL   Biochem. Biophys. Res. Commun. 360:314-319(2007).
RN   [13]
RP   INTERACTION WITH LONP2.
RX   PubMed=18281296; DOI=10.1093/jb/mvn020;
RA   Omi S., Nakata R., Okamura-Ikeda K., Konishi H., Taniguchi H.;
RT   "Contribution of peroxisome-specific isoform of Lon protease in sorting
RT   PTS1 proteins to peroxisomes.";
RL   J. Biochem. 143:649-660(2008).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [15]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT LYS-255; LYS-267; LYS-437; LYS-500
RP   AND LYS-504, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE
RP   ANALYSIS].
RX   PubMed=19608861; DOI=10.1126/science.1175371;
RA   Choudhary C., Kumar C., Gnad F., Nielsen M.L., Rehman M., Walther T.C.,
RA   Olsen J.V., Mann M.;
RT   "Lysine acetylation targets protein complexes and co-regulates major
RT   cellular functions.";
RL   Science 325:834-840(2009).
RN   [16]
RP   TISSUE SPECIFICITY, AND REVERSAL OF ACOX1 NULL PHENOTYPE IN MOUSE.
RX   PubMed=20195242; DOI=10.1038/labinvest.2010.46;
RA   Vluggens A., Andreoletti P., Viswakarma N., Jia Y., Matsumoto K., Kulik W.,
RA   Khan M., Huang J., Guo D., Yu S., Sarkar J., Singh I., Rao M.S.,
RA   Wanders R.J., Reddy J.K., Cherkaoui-Malki M.;
RT   "Reversal of mouse Acyl-CoA oxidase 1 (ACOX1) null phenotype by human
RT   ACOX1b isoform.";
RL   Lab. Invest. 90:696-708(2010).
RN   [17]
RP   ERRATUM OF PUBMED:20195242.
RA   Vluggens A., Andreoletti P., Viswakarma N., Jia Y., Matsumoto K., Kulik W.,
RA   Khan M., Huang J., Guo D., Yu S., Sarkar J., Singh I., Rao M.S.,
RA   Wanders R.J., Reddy J.K., Cherkaoui-Malki M.;
RL   Lab. Invest. 90:808-808(2010).
RN   [18]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [19]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-26, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=25944712; DOI=10.1002/pmic.201400617;
RA   Vaca Jacome A.S., Rabilloud T., Schaeffer-Reiss C., Rompais M., Ayoub D.,
RA   Lane L., Bairoch A., Van Dorsselaer A., Carapito C.;
RT   "N-terminome analysis of the human mitochondrial proteome.";
RL   Proteomics 15:2519-2524(2015).
RN   [22]
RP   VARIANTS PSEUDO-NALD CYS-178 AND VAL-278.
RX   PubMed=11815777; DOI=10.1067/mpd.2002.120511;
RA   Suzuki Y., Iai M., Kamei A., Tanabe Y., Chida S., Yamaguchi S., Zhang Z.,
RA   Takemoto Y., Shimozawa N., Kondo N.;
RT   "Peroxisomal acyl-CoA oxidase deficiency.";
RL   J. Pediatr. 140:128-130(2002).
RN   [23]
RP   VARIANTS PSEUDO-NALD VAL-64 DEL; CYS-178; LEU-184; VAL-231; VAL-278;
RP   ARG-309 AND PRO-310, AND FUNCTION.
RX   PubMed=17458872; DOI=10.1002/humu.20535;
RA   Ferdinandusse S., Denis S., Hogenhout E.M., Koster J., van Roermund C.W.,
RA   Ijlst L., Moser A.B., Wanders R.J., Waterham H.R.;
RT   "Clinical, biochemical, and mutational spectrum of peroxisomal acyl-
RT   coenzyme A oxidase deficiency.";
RL   Hum. Mutat. 28:904-912(2007).
RN   [24]
RP   INVOLVEMENT IN MITCH, VARIANT MITCH SER-237, CHARACTERIZATION OF VARIANT
RP   MITCH SER-237, SUBCELLULAR LOCATION, SUBUNIT, AND FUNCTION.
RX   PubMed=32169171; DOI=10.1016/j.neuron.2020.02.021;
RG   Members of Undiagnosed Diseases Network;
RA   Chung H.L., Wangler M.F., Marcogliese P.C., Jo J., Ravenscroft T.A.,
RA   Zuo Z., Duraine L., Sadeghzadeh S., Li-Kroeger D., Schmidt R.E.,
RA   Pestronk A., Rosenfeld J.A., Burrage L., Herndon M.J., Chen S.,
RA   Shillington A., Vawter-Lee M., Hopkin R., Rodriguez-Smith J.,
RA   Henrickson M., Lee B., Moser A.B., Jones R.O., Watkins P., Yoo T., Mar S.,
RA   Choi M., Bucelli R.C., Yamamoto S., Lee H.K., Prada C.E., Chae J.H.,
RA   Vogel T.P., Bellen H.J.;
RT   "Loss- or Gain-of-Function Mutations in ACOX1 Cause Axonal Loss via
RT   Different Mechanisms.";
RL   Neuron 106:589.e6-606.e6(2020).
CC   -!- FUNCTION: Catalyzes the desaturation of acyl-CoAs to 2-trans-enoyl-
CC       CoAs. First enzyme of the fatty acid beta-oxidation pathway.
CC       {ECO:0000269|PubMed:15060085, ECO:0000269|PubMed:17458872,
CC       ECO:0000269|PubMed:17603022, ECO:0000269|PubMed:32169171}.
CC   -!- FUNCTION: [Isoform 1]: Shows highest activity against medium-chain
CC       fatty acyl-CoAs and activity decreases with increasing chain length.
CC       {ECO:0000269|PubMed:17603022}.
CC   -!- FUNCTION: [Isoform 2]: Is active against a much broader range of
CC       substrates and shows activity towards very long-chain acyl-CoAs. Is
CC       twice as active as isoform 1 against 16-hydroxy-palmitoyl-CoA and is
CC       25% more active against 1,16-hexadecanodioyl-CoA.
CC       {ECO:0000269|PubMed:17603022}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 2,3-saturated acyl-CoA + O2 = a (2E)-enoyl-CoA + H2O2;
CC         Xref=Rhea:RHEA:38959, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:58856, ChEBI:CHEBI:65111; EC=1.3.3.6;
CC         Evidence={ECO:0000269|PubMed:17603022};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38960;
CC         Evidence={ECO:0000305|PubMed:17603022};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=hexadecanoyl-CoA + O2 = (2E)-hexadecenoyl-CoA + H2O2;
CC         Xref=Rhea:RHEA:40167, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:57379, ChEBI:CHEBI:61526;
CC         Evidence={ECO:0000269|PubMed:17603022};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40168;
CC         Evidence={ECO:0000305|PubMed:17603022};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=dodecanoyl-CoA + O2 = (2E)-dodecenoyl-CoA + H2O2;
CC         Xref=Rhea:RHEA:40171, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:57330, ChEBI:CHEBI:57375;
CC         Evidence={ECO:0000269|PubMed:17603022};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40172;
CC         Evidence={ECO:0000305|PubMed:17603022};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O2 + octanoyl-CoA = (2E)-octenoyl-CoA + H2O2;
CC         Xref=Rhea:RHEA:40175, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:57386, ChEBI:CHEBI:62242;
CC         Evidence={ECO:0000269|PubMed:17603022};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40176;
CC         Evidence={ECO:0000305|PubMed:17603022};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=decanoyl-CoA + O2 = (2E)-decenoyl-CoA + H2O2;
CC         Xref=Rhea:RHEA:40179, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:61406, ChEBI:CHEBI:61430;
CC         Evidence={ECO:0000269|PubMed:17603022};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40180;
CC         Evidence={ECO:0000305|PubMed:17603022};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O2 + tetradecanoyl-CoA = (2E)-tetradecenoyl-CoA + H2O2;
CC         Xref=Rhea:RHEA:40183, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:57385, ChEBI:CHEBI:61405;
CC         Evidence={ECO:0000269|PubMed:17603022};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40184;
CC         Evidence={ECO:0000305|PubMed:17603022};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=hexadecanedioyl-CoA + O2 = (2E)-hexadecenedioyl-CoA + H2O2;
CC         Xref=Rhea:RHEA:40275, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:77075, ChEBI:CHEBI:77085;
CC         Evidence={ECO:0000269|PubMed:17603022};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40276;
CC         Evidence={ECO:0000305|PubMed:17603022};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O2 + tetracosanoyl-CoA = (2E)-tetracosenoyl-CoA + H2O2;
CC         Xref=Rhea:RHEA:40319, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:65052, ChEBI:CHEBI:74693;
CC         Evidence={ECO:0000250|UniProtKB:P07872};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40320;
CC         Evidence={ECO:0000250|UniProtKB:P07872};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=glutaryl-CoA + O2 = (2E)-glutaconyl-CoA + H2O2;
CC         Xref=Rhea:RHEA:40315, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:57353, ChEBI:CHEBI:57378;
CC         Evidence={ECO:0000250|UniProtKB:P07872};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40316;
CC         Evidence={ECO:0000250|UniProtKB:P07872};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=hexanoyl-CoA + O2 = (2E)-hexenoyl-CoA + H2O2;
CC         Xref=Rhea:RHEA:40311, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:62077, ChEBI:CHEBI:62620;
CC         Evidence={ECO:0000250|UniProtKB:P07872};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40312;
CC         Evidence={ECO:0000250|UniProtKB:P07872};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=O2 + octadecanoyl-CoA = (2E)-octadecenoyl-CoA + H2O2;
CC         Xref=Rhea:RHEA:38971, ChEBI:CHEBI:15379, ChEBI:CHEBI:16240,
CC         ChEBI:CHEBI:57394, ChEBI:CHEBI:71412;
CC         Evidence={ECO:0000250|UniProtKB:P07872};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:38972;
CC         Evidence={ECO:0000250|UniProtKB:P07872};
CC   -!- COFACTOR:
CC       Name=FAD; Xref=ChEBI:CHEBI:57692;
CC         Evidence={ECO:0000269|PubMed:17603022};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=73 uM for palmitoyl-CoA (isoform 1) {ECO:0000269|PubMed:17603022};
CC         KM=90 uM for palmitoyl-CoA (isoform 2) {ECO:0000269|PubMed:17603022};
CC       pH dependence:
CC         Optimum pH is 8.5 for isoform 1 and 7.5-8.5 for isoform 2.
CC         {ECO:0000269|PubMed:17603022};
CC       Temperature dependence:
CC         Optimum temperature for isoform 1 at pH 7.5 is 40 degrees Celsius
CC         with no activity at 50 degrees Celsius. Optimum temperature for
CC         isoform 2 at pH 7.5 is 47.5 degrees Celsius with 57% activity
CC         retained at 50 degrees Celsius. {ECO:0000269|PubMed:17603022};
CC   -!- PATHWAY: Lipid metabolism; peroxisomal fatty acid beta-oxidation.
CC       {ECO:0000269|PubMed:17603022}.
CC   -!- SUBUNIT: Homodimer (PubMed:32169171). Interacts with LONP2
CC       (PubMed:18281296). {ECO:0000269|PubMed:18281296,
CC       ECO:0000269|PubMed:32169171}.
CC   -!- SUBCELLULAR LOCATION: Peroxisome {ECO:0000269|PubMed:32169171}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=1; Synonyms=ACOX1a, SCOX-exon 3I;
CC         IsoId=Q15067-1; Sequence=Displayed;
CC       Name=2; Synonyms=ACOX1b, SCOX-exon 3II;
CC         IsoId=Q15067-2; Sequence=VSP_000146;
CC       Name=3;
CC         IsoId=Q15067-3; Sequence=VSP_046129, VSP_000146;
CC   -!- TISSUE SPECIFICITY: Widely expressed with highest levels of isoform 1
CC       and isoform 2 detected in testis. Isoform 1 is expressed at higher
CC       levels than isoform 2 in liver and kidney while isoform 2 levels are
CC       higher in brain, lung, muscle, white adipose tissue and testis. Levels
CC       are almost equal in heart. {ECO:0000269|PubMed:17603022,
CC       ECO:0000269|PubMed:20195242}.
CC   -!- DISEASE: Adrenoleukodystrophy, pseudoneonatal (Pseudo-NALD)
CC       [MIM:264470]: A peroxisomal single-enzyme disorder of fatty acid beta-
CC       oxidation, resulting in clinical manifestations that remind neonatal
CC       adrenoleukodystrophy. Clinical features include mental retardation,
CC       leukodystrophy, seizures, mild hepatomegaly, hearing deficit. Pseudo-
CC       NALD is characterized by increased plasma levels of very-long chain
CC       fatty acids, due to decreased or absent peroxisome acyl-CoA oxidase
CC       activity. Peroxisomes are intact and functioning.
CC       {ECO:0000269|PubMed:11815777, ECO:0000269|PubMed:17458872,
CC       ECO:0000269|PubMed:8040306}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- DISEASE: Mitchell syndrome (MITCH) [MIM:618960]: A disorder
CC       characterized by episodic demyelination, sensorimotor polyneuropathy,
CC       and sensorineural hearing loss. {ECO:0000269|PubMed:32169171}. Note=The
CC       gene represented in this entry is involved in disease pathogenesis.
CC   -!- MISCELLANEOUS: Isoform 1 and isoform 2 can reverse the Acox1 null
CC       phenotype in mouse which is characterized by severe microvesicular
CC       hepatic steatosis, sustained activation of PPARA, spontaneous massive
CC       peroxisome proliferation and eventual development of hepatocellular
CC       carcinomas. Isoform 2 is more effective in reversal of the phenotype
CC       than isoform 1 (PubMed:20195242). {ECO:0000305|PubMed:20195242}.
CC   -!- SIMILARITY: Belongs to the acyl-CoA oxidase family. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=CAD97622.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; U03268; AAA19113.1; -; Genomic_DNA.
DR   EMBL; U03254; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03255; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03256; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03258; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03259; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03260; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03261; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03263; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03264; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03265; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03266; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03267; AAA19113.1; JOINED; Genomic_DNA.
DR   EMBL; U03268; AAA19114.1; -; Genomic_DNA.
DR   EMBL; U03254; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U03255; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U03257; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U03258; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U03259; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U03260; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U03261; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U03263; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U03264; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U03265; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U03266; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U03267; AAA19114.1; JOINED; Genomic_DNA.
DR   EMBL; U07866; AAA18595.1; -; mRNA.
DR   EMBL; X71440; CAA50574.1; -; mRNA.
DR   EMBL; S69189; AAB30019.2; -; mRNA.
DR   EMBL; AK291793; BAF84482.1; -; mRNA.
DR   EMBL; AK292965; BAF85654.1; -; mRNA.
DR   EMBL; AK296409; BAG59073.1; -; mRNA.
DR   EMBL; BX537380; CAD97622.1; ALT_INIT; mRNA.
DR   EMBL; AC040980; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC087289; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471099; EAW89351.1; -; Genomic_DNA.
DR   EMBL; BC008767; AAH08767.1; -; mRNA.
DR   EMBL; BC010425; AAH10425.1; -; mRNA.
DR   CCDS; CCDS11734.1; -. [Q15067-2]
DR   CCDS; CCDS11735.1; -. [Q15067-1]
DR   PIR; A54942; A54942.
DR   PIR; B54942; B54942.
DR   PIR; I38095; I38095.
DR   RefSeq; NP_001171968.1; NM_001185039.1. [Q15067-3]
DR   RefSeq; NP_004026.2; NM_004035.6. [Q15067-2]
DR   RefSeq; NP_009223.2; NM_007292.5. [Q15067-1]
DR   SMR; Q15067; -.
DR   BioGRID; 106567; 70.
DR   IntAct; Q15067; 30.
DR   STRING; 9606.ENSP00000293217; -.
DR   ChEMBL; CHEMBL4105748; -.
DR   DrugBank; DB07930; (3R)-3-HYDROXYDODECANOIC ACID.
DR   DrugBank; DB03147; Flavin adenine dinucleotide.
DR   DrugBank; DB09328; Vayarin.
DR   SwissLipids; SLP:000000536; -. [Q15067-1]
DR   SwissLipids; SLP:000000537; -. [Q15067-2]
DR   iPTMnet; Q15067; -.
DR   PhosphoSitePlus; Q15067; -.
DR   SwissPalm; Q15067; -.
DR   BioMuta; ACOX1; -.
DR   DMDM; 126302511; -.
DR   EPD; Q15067; -.
DR   jPOST; Q15067; -.
DR   MassIVE; Q15067; -.
DR   MaxQB; Q15067; -.
DR   PaxDb; Q15067; -.
DR   PeptideAtlas; Q15067; -.
DR   PRIDE; Q15067; -.
DR   ProteomicsDB; 24812; -.
DR   ProteomicsDB; 60421; -. [Q15067-1]
DR   ProteomicsDB; 60422; -. [Q15067-2]
DR   TopDownProteomics; Q15067-1; -. [Q15067-1]
DR   Antibodypedia; 19646; 378 antibodies.
DR   DNASU; 51; -.
DR   Ensembl; ENST00000293217; ENSP00000293217; ENSG00000161533. [Q15067-2]
DR   Ensembl; ENST00000301608; ENSP00000301608; ENSG00000161533. [Q15067-1]
DR   GeneID; 51; -.
DR   KEGG; hsa:51; -.
DR   UCSC; uc002jqe.5; human. [Q15067-1]
DR   CTD; 51; -.
DR   DisGeNET; 51; -.
DR   GeneCards; ACOX1; -.
DR   HGNC; HGNC:119; ACOX1.
DR   HPA; ENSG00000161533; Tissue enhanced (liver).
DR   MalaCards; ACOX1; -.
DR   MIM; 264470; phenotype.
DR   MIM; 609751; gene.
DR   MIM; 618960; phenotype.
DR   neXtProt; NX_Q15067; -.
DR   OpenTargets; ENSG00000161533; -.
DR   Orphanet; 2971; Peroxisomal acyl-CoA oxidase deficiency.
DR   PharmGKB; PA21; -.
DR   VEuPathDB; HostDB:ENSG00000161533.11; -.
DR   eggNOG; KOG0136; Eukaryota.
DR   GeneTree; ENSGT00940000157287; -.
DR   HOGENOM; CLU_014629_3_1_1; -.
DR   InParanoid; Q15067; -.
DR   OMA; GRRFFTM; -.
DR   OrthoDB; 416859at2759; -.
DR   PhylomeDB; Q15067; -.
DR   TreeFam; TF300672; -.
DR   BioCyc; MetaCyc:HS08589-MONOMER; -.
DR   BRENDA; 1.3.3.6; 2681.
DR   PathwayCommons; Q15067; -.
DR   Reactome; R-HSA-1989781; PPARA activates gene expression. [Q15067-1]
DR   Reactome; R-HSA-2046106; alpha-linolenic acid (ALA) metabolism. [Q15067-2]
DR   Reactome; R-HSA-390247; Beta-oxidation of very long chain fatty acids. [Q15067-2]
DR   Reactome; R-HSA-9033241; Peroxisomal protein import.
DR   Reactome; R-HSA-9033500; TYSND1 cleaves peroxisomal proteins.
DR   SABIO-RK; Q15067; -.
DR   SIGNOR; Q15067; -.
DR   UniPathway; UPA00661; -.
DR   BioGRID-ORCS; 51; 52 hits in 998 CRISPR screens.
DR   ChiTaRS; ACOX1; human.
DR   GeneWiki; ACOX1; -.
DR   GenomeRNAi; 51; -.
DR   Pharos; Q15067; Tbio.
DR   PRO; PR:Q15067; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   RNAct; Q15067; protein.
DR   Bgee; ENSG00000161533; Expressed in liver and 239 other tissues.
DR   ExpressionAtlas; Q15067; baseline and differential.
DR   Genevisible; Q15067; HS.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005782; C:peroxisomal matrix; TAS:Reactome.
DR   GO; GO:0005778; C:peroxisomal membrane; IEA:Ensembl.
DR   GO; GO:0005777; C:peroxisome; IDA:UniProtKB.
DR   GO; GO:0003997; F:acyl-CoA oxidase activity; IDA:UniProtKB.
DR   GO; GO:0071949; F:FAD binding; IDA:UniProtKB.
DR   GO; GO:0005504; F:fatty acid binding; IBA:GO_Central.
DR   GO; GO:0050660; F:flavin adenine dinucleotide binding; IBA:GO_Central.
DR   GO; GO:0016401; F:palmitoyl-CoA oxidase activity; IDA:UniProtKB.
DR   GO; GO:0030165; F:PDZ domain binding; IDA:MGI.
DR   GO; GO:0042803; F:protein homodimerization activity; IDA:UniProtKB.
DR   GO; GO:0047485; F:protein N-terminus binding; IPI:UniProtKB.
DR   GO; GO:0036109; P:alpha-linolenic acid metabolic process; TAS:Reactome.
DR   GO; GO:0042632; P:cholesterol homeostasis; IGI:UniProtKB.
DR   GO; GO:0033540; P:fatty acid beta-oxidation using acyl-CoA oxidase; IMP:BHF-UCL.
DR   GO; GO:0009062; P:fatty acid catabolic process; IMP:UniProtKB.
DR   GO; GO:0019395; P:fatty acid oxidation; IMP:UniProtKB.
DR   GO; GO:0006091; P:generation of precursor metabolites and energy; IMP:UniProtKB.
DR   GO; GO:0050665; P:hydrogen peroxide biosynthetic process; IMP:FlyBase.
DR   GO; GO:0055088; P:lipid homeostasis; IDA:UniProtKB.
DR   GO; GO:0006629; P:lipid metabolic process; IDA:UniProtKB.
DR   GO; GO:0016559; P:peroxisome fission; IGI:UniProtKB.
DR   GO; GO:0006693; P:prostaglandin metabolic process; IMP:UniProtKB.
DR   GO; GO:0008104; P:protein localization; TAS:Reactome.
DR   GO; GO:0019222; P:regulation of metabolic process; TAS:Reactome.
DR   GO; GO:0007283; P:spermatogenesis; IEA:Ensembl.
DR   GO; GO:0140493; P:very long-chain fatty acid beta-oxidation; IMP:UniProtKB.
DR   GO; GO:0000038; P:very long-chain fatty acid metabolic process; IMP:BHF-UCL.
DR   CDD; cd01150; AXO; 1.
DR   Gene3D; 1.10.540.10; -; 1.
DR   InterPro; IPR034171; ACO.
DR   InterPro; IPR029320; Acyl-CoA_ox_N.
DR   InterPro; IPR006091; Acyl-CoA_Oxase/DH_cen-dom.
DR   InterPro; IPR012258; Acyl-CoA_oxidase.
DR   InterPro; IPR002655; Acyl-CoA_oxidase_C.
DR   InterPro; IPR036250; AcylCo_DH-like_C.
DR   InterPro; IPR037069; AcylCoA_DH/ox_N_sf.
DR   InterPro; IPR009100; AcylCoA_DH/oxidase_NM_dom.
DR   Pfam; PF01756; ACOX; 1.
DR   Pfam; PF02770; Acyl-CoA_dh_M; 1.
DR   Pfam; PF14749; Acyl-CoA_ox_N; 1.
DR   PIRSF; PIRSF000168; Acyl-CoA_oxidase; 1.
DR   SUPFAM; SSF47203; SSF47203; 2.
DR   SUPFAM; SSF56645; SSF56645; 1.
PE   1: Evidence at protein level;
KW   Acetylation; Alternative splicing; Deafness; Disease variant; FAD;
KW   Fatty acid metabolism; Flavoprotein; Lipid metabolism; Neuropathy;
KW   Oxidoreductase; Peroxisome; Phosphoprotein; Reference proteome.
FT   CHAIN           1..660
FT                   /note="Peroxisomal acyl-CoA oxidase 1, A chain"
FT                   /id="PRO_0000204677"
FT   CHAIN           1..468
FT                   /note="Peroxisomal acyl-CoA oxidase 1, B chain"
FT                   /evidence="ECO:0000250|UniProtKB:P07872"
FT                   /id="PRO_0000447500"
FT   CHAIN           469..660
FT                   /note="Peroxisomal acyl-CoA oxidase 1, C chain"
FT                   /evidence="ECO:0000250|UniProtKB:P07872"
FT                   /id="PRO_0000447501"
FT   MOTIF           658..660
FT                   /note="Microbody targeting signal"
FT   ACT_SITE        421
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250|UniProtKB:P07872"
FT   BINDING         139
FT                   /note="FAD"
FT                   /evidence="ECO:0000250|UniProtKB:P07872"
FT   BINDING         178
FT                   /note="FAD; via amide nitrogen"
FT                   /evidence="ECO:0000250|UniProtKB:P07872"
FT   SITE            468..469
FT                   /note="Cleavage"
FT                   /evidence="ECO:0000250|UniProtKB:P07872"
FT   MOD_RES         26
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:17081983,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:23186163,
FT                   ECO:0007744|PubMed:24275569"
FT   MOD_RES         89
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         90
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         216
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         241
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         255
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         267
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         272
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         349
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         437
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         437
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         446
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         446
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         500
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         504
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0007744|PubMed:19608861"
FT   MOD_RES         512
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         512
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         542
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         637
FT                   /note="N6-acetyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         637
FT                   /note="N6-succinyllysine; alternate"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         643
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         649
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         651
FT                   /note="N6-acetyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   MOD_RES         654
FT                   /note="N6-succinyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:Q9R0H0"
FT   VAR_SEQ         1..38
FT                   /note="Missing (in isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_046129"
FT   VAR_SEQ         90..131
FT                   /note="KLHLVNFVEPVGLNYSMFIPTLLNQGTTAQKEKWLLSSKGLQ -> NFVHRG
FT                   RPEPLDLHLGMFLPTLLHQATAEQQERFFMPAWNLE (in isoform 2 and
FT                   isoform 3)"
FT                   /evidence="ECO:0000303|PubMed:14702039,
FT                   ECO:0000303|PubMed:15489334, ECO:0000303|PubMed:17974005,
FT                   ECO:0000303|PubMed:8040306"
FT                   /id="VSP_000146"
FT   VARIANT         64
FT                   /note="Missing (in pseudo-NALD)"
FT                   /evidence="ECO:0000269|PubMed:17458872"
FT                   /id="VAR_067040"
FT   VARIANT         101
FT                   /note="G -> S (in dbSNP:rs3744032)"
FT                   /id="VAR_048182"
FT   VARIANT         153
FT                   /note="T -> I (in dbSNP:rs17855420)"
FT                   /evidence="ECO:0000269|PubMed:15489334"
FT                   /id="VAR_030619"
FT   VARIANT         178
FT                   /note="G -> C (in pseudo-NALD; dbSNP:rs118204091)"
FT                   /evidence="ECO:0000269|PubMed:11815777,
FT                   ECO:0000269|PubMed:17458872"
FT                   /id="VAR_025789"
FT   VARIANT         184
FT                   /note="S -> L (in pseudo-NALD; dbSNP:rs780887410)"
FT                   /evidence="ECO:0000269|PubMed:17458872"
FT                   /id="VAR_067041"
FT   VARIANT         231
FT                   /note="G -> V (in pseudo-NALD)"
FT                   /evidence="ECO:0000269|PubMed:17458872"
FT                   /id="VAR_067042"
FT   VARIANT         237
FT                   /note="N -> S (in MITCH; gain-of-function; increased
FT                   dimerization; increased protein levels and peroxisomal
FT                   acyl-coenzyme A oxidase function; increased levels of
FT                   reactive oxygen species; no effect on VLCFA levels; no
FT                   effect on peroxisome location; causes Schwann cell death
FT                   and myelination defects; dbSNP:rs1567876984)"
FT                   /evidence="ECO:0000269|PubMed:32169171"
FT                   /id="VAR_083893"
FT   VARIANT         278
FT                   /note="M -> V (in pseudo-NALD; dbSNP:rs118204090)"
FT                   /evidence="ECO:0000269|PubMed:11815777,
FT                   ECO:0000269|PubMed:17458872"
FT                   /id="VAR_025790"
FT   VARIANT         309
FT                   /note="Q -> R (in pseudo-NALD; dbSNP:rs118204092)"
FT                   /evidence="ECO:0000269|PubMed:17458872"
FT                   /id="VAR_067043"
FT   VARIANT         310
FT                   /note="S -> P (in pseudo-NALD; dbSNP:rs758962364)"
FT                   /evidence="ECO:0000269|PubMed:17458872"
FT                   /id="VAR_067044"
FT   VARIANT         312
FT                   /note="I -> M (in dbSNP:rs1135640)"
FT                   /evidence="ECO:0000269|PubMed:14702039,
FT                   ECO:0000269|PubMed:15489334, ECO:0000269|PubMed:17974005,
FT                   ECO:0000269|PubMed:8040306, ECO:0000269|PubMed:8117268"
FT                   /id="VAR_021529"
FT   CONFLICT        27
FT                   /note="P -> L (in Ref. 3; CAA50574)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        80
FT                   /note="A -> R (in Ref. 3; CAA50574)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        84
FT                   /note="E -> D (in Ref. 6; CAD97622)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        119
FT                   /note="Q -> E (in Ref. 4; AAB30019)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        200
FT                   /note="Y -> H (in Ref. 2; AAA18595)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        212..213
FT                   /note="IG -> NR (in Ref. 1; AAA19113/AAA19114 and 2;
FT                   AAA18595)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        264
FT                   /note="T -> P (in Ref. 1; AAA19113/AAA19114 and 2;
FT                   AAA18595)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        332
FT                   /note="F -> L (in Ref. 2; AAA18595)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        449
FT                   /note="C -> R (in Ref. 2; AAA18595)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        490
FT                   /note="R -> L (in Ref. 5; BAF85654)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        531
FT                   /note="C -> L (in Ref. 1; AAA19113/AAA19114 and 2;
FT                   AAA18595)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        534..535
FT                   /note="VV -> GL (in Ref. 1; AAA19113/AAA19114 and 2;
FT                   AAA18595)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        615
FT                   /note="V -> A (in Ref. 3; CAA50574)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        650
FT                   /note="Y -> YH (in Ref. 4; AAB30019)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   660 AA;  74424 MW;  D713768A47374EA1 CRC64;
     MNPDLRRERD SASFNPELLT HILDGSPEKT RRRREIENMI LNDPDFQHED LNFLTRSQRY
     EVAVRKSAIM VKKMREFGIA DPDEIMWFKK LHLVNFVEPV GLNYSMFIPT LLNQGTTAQK
     EKWLLSSKGL QIIGTYAQTE MGHGTHLRGL ETTATYDPET QEFILNSPTV TSIKWWPGGL
     GKTSNHAIVL AQLITKGKCY GLHAFIVPIR EIGTHKPLPG ITVGDIGPKF GYDEIDNGYL
     KMDNHRIPRE NMLMKYAQVK PDGTYVKPLS NKLTYGTMVF VRSFLVGEAA RALSKACTIA
     IRYSAVRHQS EIKPGEPEPQ ILDFQTQQYK LFPLLATAYA FQFVGAYMKE TYHRINEGIG
     QGDLSELPEL HALTAGLKAF TSWTANTGIE ACRMACGGHG YSHCSGLPNI YVNFTPSCTF
     EGENTVMMLQ TARFLMKSYD QVHSGKLVCG MVSYLNDLPS QRIQPQQVAV WPTMVDINSP
     ESLTEAYKLR AARLVEIAAK NLQKEVIHRK SKEVAWNLTS VDLVRASEAH CHYVVVKLFS
     EKLLKIQDKA IQAVLRSLCL LYSLYGISQN AGDFLQGSIM TEPQITQVNQ RVKELLTLIR
     SDAVALVDAF DFQDVTLGSV LGRYDGNVYE NLFEWAKNSP LNKAEVHESY KHLKSLQSKL
//
